entity

PET

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about PET: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

3Connections
18Hypotheses
2Analyses
2Outgoing
1Incoming
20Experiments
2Debates

No AI portrait yet

Wiki Pages (21)

Knowledge base pages for this entity

Canonical Page

PI-2620 Tau PET in PSP

clinical · 5625 words

PET Imaging in Neurodegeneration

diagnostic · 3238 words

TSPO PET Imaging for Neuroinflammation

mechanism · 2954 words

XTR006 Tau PET for AD (NCT07115238)

clinical · 2889 words

Computational Tau Propagation Model Validation with PET Imaging

mechanism · 2593 words

Tau PET Imaging

diagnostic · 2495 words

Outgoing (2)

TargetRelationTypeStr
Parkinson's Diseasebiomarker_fordisease0.85
MOLECULAR_IMAGINGregulatesphenotype0.72

Incoming (1)

SourceRelationTypeStr
COMPOSITE_BIOMARKERco_associated_withgene0.30

Targeting Hypotheses (18)

Hypotheses where this entity is a therapeutic target

HypothesisScoreDiseaseAnalysis
Multi-Biomarker Composite Index Surpassing Amyloid PET for T 0.933 neurodegeneration What amyloid threshold level is required
Competitive APOE4 Domain Stabilization Peptides 0.784 neurodegeneration APOE4 structural biology and therapeutic
NLRP3 Inflammasome Lock Perpetuates Senescence-Associated In 0.720 neurodegeneration What molecular mechanisms drive microgli
C1q-TREM2 Competition for Phosphatidylserine as Pruning Chec 0.680 Alzheimer's disease -
Competition-based domain allocation 0.650 neurodegeneration View
Glycine-Rich Domain Competitive Inhibition 0.640 neurodegeneration TDP-43 phase separation therapeutics for
H2: H3K9me3 Heterochromatin Collapse Enables Cryptic Transcr 0.610 neurodegeneration Investigate mechanisms of epigenetic rep
Temporal Decoupling of CSF p-tau217 Normalization from Amylo 0.595 neurodegeneration -
TREM2-C1Q Competitive Binding to Prevent Complement-Mediated 0.591 neurodegeneration Do β-amyloid plaques and neurofibrillary
Competition with G3BP1-Caprin1/FMRP Scaffold Formation 0.590 neurodegeneration How does TRIM21-mediated K63 ubiquitinat
Peri-plaque tau seeding restraint via TREM2-competent microg 0.590 neurodegeneration Does the cancer-cystatin-C-TREM2 pathway
P2X7R PET Imaging for NLRP3 Inflammasome-Associated Priming 0.560 biomarkers What biomarkers can reliably detect micr
TSPO PET Kinetic Modeling for Priming State Discrimination 0.530 biomarkers What biomarkers can reliably detect micr
Soluble GAG-Mimetic Peptides Compete with HSPG for Tau Seed 0.510 neurodegeneration Investigate prion-like spreading of tau
CX3CR1 PET with Nano-bodies for Microglial Surveillance Stat 0.500 biomarkers What biomarkers can reliably detect micr
Shift AQP4 Isoform/OAP Assembly Toward Clearance-Competent A 0.500 neurodegeneration How can AQP4 be effectively targeted the
Transcriptome-wide competition determines functional selecti 0.490 molecular neurobiology How does lncRNA-0021 achieve sequence-sp
RNA-Binding Competition Therapy for TDP-43 Cross-Seeding 0.465 neurodegeneration Protein aggregation cross-seeding across

Mentioning Analyses (2)

Scientific analyses that reference this entity

Blood-brain barrier permeability changes as early biomarkers for neurodegenerati

neurodegeneration | 2026-04-26 | 5 hypotheses Top: 0.712

What amyloid threshold level is required for optimal clinical benefit in early A

neurodegeneration | 2026-04-16 | 2 hypotheses Top: 0.933

Experiments (20)

Experimental studies targeting or related to this entity

ExperimentTypeDiseaseScoreFeasibilityModelStatusEst. Cost
GWAS of plasma NfL in East Asian cohort exploratory Alzheimer's disease 0.950 0.00 human patients - East Asian co proposed N/A
GWAS of plasma pTau217 in East Asian cohort exploratory Alzheimer's disease 0.950 0.00 human patients - East Asian co proposed N/A
Dairy intake and dementia risk in Malmö Diet and Cancer cohort clinical Alzheimer's disease 0.950 0.00 Swedish community-based adults proposed N/A
GWAS of plasma pTau181 in East Asian cohort exploratory Alzheimer's disease 0.950 0.00 human patients - East Asian co proposed N/A
GWAS of plasma GFAP in East Asian cohort exploratory Alzheimer's disease 0.950 0.00 human patients - East Asian co proposed N/A
KEEPS Continuation: Long-term effects of menopausal hormone therapy on clinical Alzheimer's disease 0.950 0.00 recently menopausal women with proposed N/A
GWAS of composite biomarker score exploratory Alzheimer's disease 0.900 0.00 human patients - East Asian co proposed N/A
RBG treatment in ApoE-/- atherosclerosis mouse model validation atherosclerosis 0.900 0.00 ApoE-/- mice proposed N/A
TDP-43 mutant mouse model cGAS/STING pathway analysis validation amyotrophic lateral sclerosis 0.900 0.00 TDP-43 mutant mice proposed N/A
TDP-43 mitochondrial invasion and DNA release via mPTP exploratory amyotrophic lateral sclerosis 0.900 0.00 cultured cells proposed N/A
TDP-43 mitochondrial invasion and mtDNA release in iPSC motor neurons exploratory Amyotrophic Lateral Sclerosis 0.900 0.00 iPSC-derived motor neurons proposed N/A
LPS-induced mouse model of depression with synaptic loss analysis validation depression 0.900 0.00 LPS-treated mice proposed N/A
Bidirectional Mendelian randomization analysis of C1Q and ischemic str exploratory Ischemic stroke, Atheroscleros 0.900 0.00 Human genetic association data proposed N/A
Bidirectional Mendelian randomization analysis of C1Q and ischemic str exploratory Ischemic stroke (large artery 0.900 0.00 human genetic data proposed N/A
cGAS/STING pathway validation in TDP-43 mutant mice validation Amyotrophic Lateral Sclerosis 0.850 0.00 TDP-43 mutant mice proposed N/A
C1q neutralizing antibody intervention in depression model validation depression 0.850 0.00 LPS-treated mice with C1q anti proposed N/A
cGAMP biomarker analysis in ALS patient spinal cord samples exploratory Amyotrophic Lateral Sclerosis 0.800 0.00 Human ALS patient spinal cord proposed N/A
TDP-43 pathology prevalence and distribution in AD cases exploratory Alzheimer's disease 0.800 0.00 human postmortem brain tissue proposed N/A
APOE4 association with TDP-43 pathology in AD exploratory Alzheimer's disease 0.750 0.00 human patients proposed N/A
Cognitive impact of TDP-43 pathology in AD patients clinical Alzheimer's disease 0.700 0.00 human patients proposed N/A

Related Papers (20)

Scientific publications cited in analyses involving this entity

Title & PMIDAuthorsJournalYearCitations
Autophagy and ALS: mechanistic insights and therapeutic implications. [PMID:34057020] Chua JP, De Calbiac H, Kabashi E, Barmad Autophagy 2022 2
TDP-43 Pathology in Alzheimer's Disease. [PMID:34930382] Meneses A, Koga S, O'Leary J, Dickson DW Mol Neurodegener 2021 2
Protein transmission in neurodegenerative disease. [PMID:32203399] Peng C, Trojanowski JQ, Lee VM Nat Rev Neurol 2020 2
TDP-43 Triggers Mitochondrial DNA Release via mPTP to Activate cGAS/STING in ALS [PMID:33031745] Yu CH, Davidson S, Harapas CR, Hilton JB Cell 2020 2
Trehalose induces autophagy via lysosomal-mediated TFEB activation in models of [PMID:30335591] Rusmini P, Cortese K, Crippa V, Cristofa Autophagy 2019 2
Amelioration of Tau and ApoE4-linked glial lipid accumulation and neurodegenerat [PMID:37995685] Litvinchuk A, Suh JH, Guo JL, Lin K, Dav Neuron 2024 1
N protein of PEDV plays chess game with host proteins by selective autophagy. [PMID:36861818] Zhai X, Kong N, Zhang Y, Song Y, Qin W, Autophagy 2023 1
PIKFYVE inhibition mitigates disease in models of diverse forms of ALS. [PMID:36754049] Hung ST, Linares GR, Chang WH, Eoh Y, Kr Cell 2023 1
The APOE-R136S mutation protects against APOE4-driven Tau pathology, neurodegene [PMID:37957317] Maxine R Nelson, Peng Liu, Ayushi Agrawa Nature neuroscience 2023 1
APOE and Alzheimer's disease: advances in genetics, pathophysiology, and therape [PMID:33340485] Serrano-Pozo A, Das S, Hyman BT Lancet Neurol 2021 1
Lysosome-targeting chimaeras for degradation of extracellular proteins. [PMID:32728216] Banik SM, Pedram K, Wisnovsky S, Ahn G, Nature 2020 1
Alzheimer Disease: An Update on Pathobiology and Treatment Strategies. [PMID:31564456] Long JM, Holtzman DM Cell 2019 1
Selective Silencing of TDP-43 P. G376D Mutation Reverses Key Amyotrophic Lateral [PMID:41897327] Romano R, Ruotolo G, Perrone F, Tomasell Biomolecules 2026 0
Plasma GFAP outperforms CSF GFAP in detecting amyloid pathology and is associate [PMID:41905188] Cetindag AC, Schipke CG, Esselmann H, Kr The journal of prevention of A 2026 0
Modulation of apolipoprotein E receptor-2 by ApoE4, amyloid β-peptide, reelin, a [PMID:41858499] ["Barger S", "Moerman-Herzog A"] Frontiers in molecular neurosc 2026 0
Chemical and Molecular Strategies in Restoring Autophagic Flux in TDP-43 Protein [PMID:41900026] Jamerlan A, Hulme J Molecules (Basel, Switzerland) 2026 0
ASS1 Promotes Atherosclerotic Inflammation Through the NLRP3/IL-33/ST2 Axis in O [PMID:41914296] Wu S, Han F, Qiao Z, Yuan S, Bian X, Zha Frontiers in bioscience (Landm 2026 0
Axonal transport impairment as an upstream mechanism in amyotrophic lateral scle [PMID:41890591] Gabbay U Frontiers in neuroscience 2026 0
CRISPR-based correction of apolipoprotein E4 in Alzheimer's disease: Therapeutic [PMID:41812941] ["Wang M", "Niu D", "Zhang Q", "Tang Y", International journal of biolo 2026 0
Defining RNA oligonucleotides that reverse deleterious phase transitions of RNA- [PMID:41512823] ["Guo L", "Mann J", "Mauna J", "Copley K Molecular cell 2026 0

Debates (2)

Multi-agent debates referencing this entity

Blood-brain barrier permeability changes as early biomarkers for neurodegenerati

active · Rounds: 7 · Score: 0.00 · 2026-04-26

While the study demonstrates dose-response relationships between amyloid levels

closed · Rounds: 4 · Score: 0.76 · 2026-04-16

Related Research

Hypotheses and analyses mentioning PET in their description or question text

Glycine-Rich Domain Competitive Inhibition

Score: 0.640 · neurodegeneration · 2026-04-02

## Mechanistic Overview Glycine-Rich Domain Competitive Inhibition starts from the claim that modulating TARDBP within t

H2: H3K9me3 Heterochromatin Collapse Enables Cryptic Transcription of Repetitive

Score: 0.610 · neurodegeneration · 2026-04-22

## Mechanistic Overview H2: H3K9me3 Heterochromatin Collapse Enables Cryptic Transcription of Repetitive Elements starts

TREM2-C1Q Competitive Binding to Prevent Complement-Mediated Cholinergic Synapse

Score: 0.591 · neurodegeneration · 2026-04-16

**Molecular Mechanism and Rationale** The TREM2-C1Q competitive binding hypothesis centers on the intricate molecular i

Competition with G3BP1-Caprin1/FMRP Scaffold Formation

Score: 0.590 · neurodegeneration · 2026-04-21

**Molecular Mechanism and Rationale** The hypothesis centers on the critical role of G3BP1 (Ras GTPase-activating prote

Peri-plaque tau seeding restraint via TREM2-competent microglia

Score: 0.590 · neurodegeneration · 2026-04-25

TREM2-activated microglia limit neuritic plaque tau spread around amyloid plaques through enhanced phagocytosis of extra

P2X7R PET Imaging for NLRP3 Inflammasome-Associated Priming

Score: 0.560 · biomarkers · 2026-04-22

## Mechanistic Overview P2X7R PET Imaging for NLRP3 Inflammasome-Associated Priming starts from the claim that modulatin

TSPO PET Kinetic Modeling for Priming State Discrimination

Score: 0.530 · biomarkers · 2026-04-22

## Mechanistic Overview TSPO PET Kinetic Modeling for Priming State Discrimination starts from the claim that modulating

Soluble GAG-Mimetic Peptides Compete with HSPG for Tau Seed Binding and Prevent

Score: 0.510 · neurodegeneration · 2026-04-22

## Mechanistic Overview Soluble GAG-Mimetic Peptides Compete with HSPG for Tau Seed Binding and Prevent Cellular Uptake

CX3CR1 PET with Nano-bodies for Microglial Surveillance State Mapping

Score: 0.500 · biomarkers · 2026-04-22

## Mechanistic Overview CX3CR1 PET with Nano-bodies for Microglial Surveillance State Mapping starts from the claim that

Shift AQP4 Isoform/OAP Assembly Toward Clearance-Competent Autoantibody-Less-Clu

Score: 0.500 · neurodegeneration · 2026-04-21

## Mechanistic Overview Shift AQP4 Isoform/OAP Assembly Toward Clearance-Competent Autoantibody-Less-Clustered State sta

Transcriptome-wide competition determines functional selectivity after direct bi

Score: 0.490 · molecular neurobiology · 2026-04-25

lncRNA-0021 may not be uniquely specific at the physical binding level; instead, its apparent selectivity for mmu-miR-63

RNA-Binding Competition Therapy for TDP-43 Cross-Seeding

Score: 0.465 · neurodegeneration · 2026-04-02

Synthetic RNA aptamers designed to competitively bind TDP-43's RNA recognition motifs could prevent its interaction with